Fig. 2From: Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysisRecurrence-free (left, p < 0.01) and overall survival (right, p = 0.01) among all stage III patients stratified by adjuvant NY-ESO-1 vaccine versus no adjuvant therapyBack to article page